Correlation of MicroRNA 132 up-regulation with an unfavorable clinical outcome in patients with primary glioblastoma multiforme treated with radiotherapy plus concomitant and adjuvant temozolomide chemotherapy

Translational Oncology

Volumn 6, Issue 6, 2013, Pages 742-748

  Parker, Nicole R ^a,b   Correia, Nelson ^b   Crossley, Brendan ^b   Buckland, Michael E ^b,c   Howell, Viive M ^a,b   Wheeler, Helen R ^a,b,d,e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e North Shore Private Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA 132; TEMOZOLOMIDE;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GLIOBLASTOMA; HUMAN; MALE; METHYLATION; RADIATION DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; UPREGULATION;

EID: 84891684280     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13553     Document Type: Article

References (47)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459-466.
3. Ambros V (2004). The functions of animal microRNAs. Nature 431, 350-355.
4. Friedman RC, Farh KK, Burge CB, and Bartel DP (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19, 92-105.
5. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al. (2002). Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99, 15524-15529.
6. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, and Dahlberg JE (2005). Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 102, 3627-3632.
7. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435, 834-838.
8. Nana-Sinkam SP and Croce CM (2013). Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93, 98-104.
9. Ren Y, Zhou X, Mei M, Yuan XB, Han L, Wang GX, Jia ZF, Xu P, Pu PY, and Kang CS (2010). MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 10, 27.
10. Ren Y, Kang CS, Yuan XB, Zhou X, Xu P, Han L, Wang GX, Jia Z, Zhong Y, Yu S, et al. (2010). Co-delivery of as-miR-21 and 5-FU by poly (amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed 21, 303-314.
11. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103, 2257-2261.
12. Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, et al. (2010). MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 16, 909-914.
13. Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH, Westbrook GL, Mandel G, and Goodman RH (2010). MicroRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus. Proc Natl Acad Sci USA 107, 20382-20387.
14. Kawashima H, Numakawa T, Kumamaru E, Adachi N, Mizuno H, Ninomiya M, Kunugi H, and Hashido K (2010). Glucocorticoid attenuates brain-derived neurotrophic factor-dependent upregulation of glutamate receptors via the suppression of microRNA-132 expression. Neuroscience 165, 1301-1311.
15. Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, and Soreq H (2009). MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity 31, 965-973.
16. Yang D, Li T, Wang Y, Tang Y, Cui H, Zhang X, Chen D, Shen N, and Le W (2012). miR-132 regulates the differentiation of dopamine neurons by directly targeting Nurr1 expression. J Cell Sci 125, 1673-1682.
17. Lee ST, Chu K, Im WS, Yoon HJ, Im JY, Park JE, Park KH, Jung KH, Lee SK, Kim M, et al. (2011). Altered microRNA regulation in Huntington's disease models. Exp Neurol 227, 172-179.
18. Miller BH, Zeier Z, Xi L, Lanz TA, Deng S, Strathmann J, Willoughby D, Kenny PJ, Elsworth JD, Lawrence MS, et al. (2012). MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci USA 109, 3125-3130.
19. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al. (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med 360, 765-773.
20. Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, Araki Y, Kuga D, Nakamizo A, Amano T, et al. (2010). MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res 16, 4289-4297.
21. Pereira DM, Rodrigues PM, Borralho PM, and Rodrigues CM (2012). Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 18, 282-289.
22. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997-1003.
23. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, and Aldape KD (2010). MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12, 116-121.
24. Wanet A, Tacheny A, Arnould T, and Renard P (2012). miR-212/132 expression and functions: within and beyond the neuronal compartment. Nucleic Acids Res 40, 4742-4753.
25. Alvarez-Saavedra M, Antoun G, Yanagiya A, Oliva-Hernandez R, Cornejo-Palma D, Perez-Iratxeta C, Sonenberg N, and Cheng HY (2011). miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock. Hum Mol Genet 20, 731-751.
26. Park JK, Henry JC, Jiang J, Esau C, Gusev Y, Lerner MR, Postier RG, Brackett DJ, and Schmittgen TD (2011). miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun 406, 518-523.
27. Wayman GA, Davare M, Ando H, Fortin D, Varlamova O, Cheng HY, Marks D, Obrietan K, Soderling TR, Goodman RH, et al. (2008). An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP. Proc Natl Acad Sci USA 105, 9093-9098.
28. Huang Y, Lei Y, Zhang H, Hou L, Zhang M, and Dayton AI (2011). Micro-RNA regulation of STAT4 protein expression: rapid and sensitive modulation of IL-12 signaling in human natural killer cells. Blood 118, 6793-6802.
29. Molnár V, Érsek B, Wiener Z, Tömböl Z, Szabó PM, Igaz P, and Falus A (2012). MicroRNA-132 targets HB-EGF upon IgE-mediated activation in murine and human mast cells. Cell Mol Life Sci 69, 793-808.
30. Smith PY, Delay C, Girard J, Papon MA, Planel E, Sergeant N, Buée L, and Hébert SS (2011). MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum Mol Genet 20, 4016-4024.
31. Strum JC, Johnson JH, Ward J, Xie H, Feild J, Hester A, Alford A, and Waters KM (2009). MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1. Mol Endocrinol 23, 1876-1884.
32. Ucar A, Vafaizadeh V, Jarry H, Fiedler J, Klemmt PA, Thum T, Groner B, and Chowdhury K (2010). miR-212 and miR-132 are required for epithelial stromal interactions necessary for mouse mammary gland development. Nat Genet 42, 1101-1108.
33. Carrillo ED, Escobar Y, González G, Hernández A, Galindo JM, García MC, and Sáanchez JA (2011). Posttranscriptional regulation of the β2-subunit of cardiac L-type Ca2+ channels by microRNAs during long-term exposure to isoproterenol in rats. J Cardiovasc Pharmacol 58, 470-478.
34. Cheng HY, Papp JW, Varlamova O, Dziema H, Russell B, Curfman JP, Nakazawa T, Shimizu K, Okamura H, Impey S, et al. (2007). MicroRNA modulation of circadian-clock period and entrainment. Neuron 54, 813-829.
35. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, and Chan EK (2008). Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 10, R101.
36. Panicker SP, Raychaudhuri B, Sharma P, Tipps R, Mazumdar T, Mal AK, Palomo JM, Vogelbaum MA, and Haque SJ (2010). p300-and Myc-mediated regulation of glioblastoma multiforme cell differentiation. Oncotarget 1, 289-303.
37. de Groot J and Sontheimer H (2011). Glutamate and the biology of gliomas. Glia 59, 1181-1189.
38. Lages E, Guttin A, El Atifi M, Ramus C, Ipas H, Dupré I, Rolland D, Salon C, Godfraind C, deFraipont F, et al. (2011). MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS One 6, e20600.
39. Zitvogel L, Apetoh L, Ghiringhelli F, and Kroemer G (2008). Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8, 59-73.
40. Little AS, Smith PD, and Cook SJ (2013). Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene 32, 1207-1215.
41. Yang YP, Chien Y, Chiou GY, Cherng JY, Wang ML, Lo WL, Chang YL, Huang PI, Chen YW, Shih YH, et al. (2012). Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 33, 1462-1476.
42. van Rooij E, Purcell AL, and Levin AA (2012). Developing microRNA therapeutics. Circ Res 110, 496-507.
43. Lagos D, Pollara G, Henderson S, Gratrix F, Fabani M, Milne RS, Gotch F, and Boshoff C (2010). miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Nat Cell Biol 12, 513-519.
44. Numakawa T, Yamamoto N, Chiba S, Richards M, Ooshima Y, Kishi S, Hashido K, Adachi N, and Kunugi H (2011). Growth factors stimulate expression of neuronal and glial miR-132. Neurosci Lett 505, 242-247.
45. Godoy J, Nishimura M, and Webster NJ (2011). Gonadotropin-releasing hormone induces miR-132 and miR-212 to regulate cellular morphology and migration in immortalized LβT2 pituitary gonadotrope cells. Mol Endocrinol 25, 810-820.
46. Jimenez-Mateos EM, Bray I, Sanz-Rodriguez A, Engel T, McKiernan RC, Mouri G, Tanaka K, Sano T, Saugstad JA, Simon RP, et al. (2011). miRNA expression profile after status epilepticus and hippocampal neuroprotection by targeting miR-132. Am J Pathol 179, 2519-2532.
47. Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, Blay JY, and Alberti L (2010). Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer 129, 680-690.